TEVA.N Teva Pharmaceutical Industries Limited Sponsored ADR

TEVA INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Teva Pharmaceutical Industries Limited

NEW YORK--(BUSINESS WIRE)--

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Teva Pharmaceutical Industries Limited (“Teva”) (NYSE:TEVA) violated federal securities laws.

Click here to learn about the case: http://docs.wongesq.com/TEVA-Request-Form-1686. There is no cost or obligation to you.

On August 2, 2016, Teva completed its acquisition of Allergan plc’s generics business, Actavis Generis. Teva continued to make positive statements concerning the integration of the business, growth on intangible assets and goodwill, and general benefits of the acquisition. Then on August 3, 2017, Teva lowered its outlook and recorded a $6.1 billion impairment charge.

To learn more about the investigation of Teva contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/TEVA-Request-Form-1686.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
29/08/2017

Underlying

TEVA.NTeva Pharmaceutical Industries Limited Sponsored ADR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teva Pharmaceutical Industries Limited Sponsored ADR

 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva and Blackstone Life Sciences Announce $400 Million Strategic Grow...

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1ADuvakitug is currently in phase 3 clinical studies for ulcerative colitis (UC) and Crohn’s disease (CD)Agreement supports Teva’s Pivot to Growth strategy to accelerate its innovative pipeline and drive long-term growth PARSIPPANY, N.J. and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutic...

March 3, 2026 1 EN
Free Trial
TEVA.N Teva Pharmaceut...

Teva Pharmaceutical Industries Ltd: 1 director

A director at Teva Pharmaceutical Industries Ltd sold 345,810 shares at 33.645USD and the significance rating of the trade was 95/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...

TEVA.N TEVA PHARMACEUTICAL INDUSTRIES LIMITED SPONSORED ADR
03/03/26 March 3, 2026 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva to Present at the Upcoming Investor Conferences in March

Teva to Present at the Upcoming Investor Conferences in March PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the upcoming investor conferences in March as follows: UBS European Healthcare Conference Tuesday, March 3, 2026 (investor meetings only – no webcast)Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026, at 10:00 am ET (webcast fireside chat)Barclays 28th Annual Global Healthcare ConferenceTuesday, Mar...

February 24, 2026 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Applic...

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation1If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1Teva is committed to advancing this innovative treat...

February 20, 2026 1 EN
 PRESS RELEASE
Free
TEVA.N Teva Pharmaceut...

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated cli...

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of inductionDuvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ...

February 17, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch